Emelianenko-Mitrione bout postponed due to American’s illnessSport February 19, 4:06
OSCE unable to identify perpetrators of cyber attacks against it - secretary generalWorld February 19, 4:02
Russian biathletes win gold in relay at 2017 IBU World Championships in AustriaSport February 18, 18:30
Putin signs decree on recognition of documents given to Donbass peopleRussian Politics & Diplomacy February 18, 17:26
Sberbank CEO says no repeat of crisis in the short termBusiness & Economy February 18, 17:24
Judging by certain statements at Munich Conference, "cold war" is still not over — LavrovRussian Politics & Diplomacy February 18, 15:19
Bout’s lawyers will challenge Court of Appeals’ decision in Supreme Court on February 21Russian Politics & Diplomacy February 18, 7:16
Turkish Minister reproaches NATO for not fulfilling obligations on its south-eastern flankWorld February 18, 7:12
Moody's upgrades outlook on Russia’s sovereign rating to stable from negativeBusiness & Economy February 18, 2:37
GENEVA, October 3. /TASS/. The Court of Arbitration for Sport (CAS) is set to announce a decision on the appeal of Russian tennis star Maria Sharapova, submitted in summer against her two-year ban, on Tuesday, October 4, the court said in its statement on Monday.
"Decision in the case of Maria Sharapova v. International Tennis Federation to be released at 3.00 pm (Swiss time) on 4 October 2016," the statement said.
On June 9, Sharapova filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed on June 8 by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
Due to the imposed ban world’s former No. 1 Sharapova had to miss the 2016 Summer Olympic Games, held in August in Brazil’s Rio de Janeiro.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.